3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Recruiting
2
Terminated
1
Completed
1
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Myeloid
1
Classical hematology
1
Conditions
Anemia
2
beta-Thalassemia
1
Primary Myelofibrosis
1
Myelodysplastic Syndromes
1
Granulosa cell tumor of the ovary
1
Interventions
Cyclophosphamide
110
fludarabine phosphate
106
Busulfan
84
Azacitidine
73
Peripheral Blood Stem Cell Transplantation
64
Mycophenolic Acid
64
Antilymphocyte Serum
64
Cytarabine
63
Tacrolimus
62
fludarabine
61
Cyclosporine
56
Filgrastim
55
Whole-Body Irradiation
52
Methotrexate
47
Melphalan
42
Decitabine
42
Radiotherapy
37
Clofarabine
29
Granulocyte Colony-Stimulating Factor
28
Cord Blood Stem Cell Transplantation
28
Methylprednisolone
24
Etoposide
24
thymoglobulin
21
Thiotepa
21
Stem Cell Transplantation
21
sargramostim
19
Sirolimus
16
Alemtuzumab
15
Lenalidomide
13
Gemtuzumab
13
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Completed
×
Myelodysplastic Syndromes
×
luspatercept
×
Clear all
NCT02631070
2021-12-17
MEDALIST
Celgene
Phase 3
Completed
229 enrolled
36 charts
1 FDA